Craig... you know that we found out Leronlimab act

Craig... you know that we found out Leronlimab actually worked right? 24% is pretty good and Nader mentioned if you use a factor of the over 65 allowed for some endpoints it could of been as good as 40% life saving. We couldn’t use it for mortality because it was our primary end point I guess. I would say 24+% is awesome.

Instead of trying to prove that hard to prove percentages for mortality and trying to get p value in critical as our main primary endpoint. Cytodyn decided to use an endpoint that we knew we could guarantee a EUA and a BLA.

I would consider that great news. This is our future home run or as easy as a lay up if your hooping. Whatever analogy you want to use. We are going to go a short time in a short trial and have an EUA. Our results for mortality will still shine through and might be better in the next trial but the risk in our Potential EUA is drastically reduced to a lay up. Revenue is made this way. Investments are safe this way. This is great news for investors and for people that need Leronlimab to save their lives. We will finally have revenue to push our narrative of other trials and paying our way to BLA’s for indications to come. How can you not see the optimistic view of this weekend news releases. They assured you that you will be updated at least bi-weekly or more often. Bottom line is we have less than 6 months but as early as 3-4 months until guaranteed revenue. Then add in possible revenue from other countries looking to get in early before our EUA on a drug they know works and maybe works better than we know with a another small trial coming to confirm. We are sitting pretty good in my eyes.